5-异硫氰酸茚酯 | 149865-84-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 5-异硫氰酸茚酯
• 英文名称: indan-5-yl isothiocyanate
• 英文别名: 5-indanyl isothiocyanate；(2,3-dihydro-1H-inden-5-yl)isothiocyanate；5-isothiocyanato-2,3-dihydro-1H-indene；indan-5-yl-isothiocyanate；5-indanyl-isothiocyanate
• CAS: 149865-84-9
• 化学式: C₁₀H₉NS
• mdl: MFCD00060338
• 分子量: 175.254
• InChiKey: DRZNKOAIZHUADV-UHFFFAOYSA-N

物化性质

• 沸点：
  99°C/1mm
• 密度：
  1.15

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT, KEEP COLD

反应信息

• 作为反应物：
  描述：

  5-异硫氰酸茚酯 在 肼基甲酸叔丁酯 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 (Z)-N-(2,3-dihydro-1H-inden-5-yl)-2-(2-oxoindolin-3-ylidene)hydrazinecarbothioamide
  参考文献：
  名称：

  Synthesis and Structure–Activity Evaluation of Isatin-β-thiosemicarbazones with Improved Selective Activity toward Multidrug-Resistant Cells Expressing P-Glycoprotein

  摘要：

  Cancer multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters presents a significant unresolved clinical challenge. One strategy to resolve MDR is to develop compounds that selectively kill cells overexpressing the efflux transporter P-glycoprotein (MDR1, P-gp, ABCB1). We have previously reported structure-activity studies based around the lead compound NSC73306 (1, 1-isatin-4-(4'-methoxyphenyl)-3-thiosemicarbazone, 4.3-fold selective). Here we sought to extend this work on MDR1-selective analogues by establishing whether 1 showed "robust" activity against a range of cell lines expressing P-gp. We further aimed to synthesize and test analogues with varied substitution at the N4-position, and substitution around the N4-phenyl ring of isatin-beta-thiosemicarbazones (IBTs), to identify compounds with increased MDR1-selectivity. Compound 1 demonstrated MDR1-selectivity against all P-gp-expressing cell lines examined. This selectivity was reversed by inhibitors of P-gp ATPase activity. Structural variation at the 4'-phenyl position of 1 yielded compounds of greater MDR1-selectivity. Two of these analogues, 1-isatin-4-(4'-nitrophenyl)-3-thiosemicarbazone (22, 8.3-fold selective) and 1-isatin-4-(4'-tert-butyl phenyl)-3-thiosemicarbazone (32, 14.8-fold selective), were selected for further testing and were found to retain the activity profile of 1. These compounds are the most active IBTs identified to date.

  DOI：

  10.1021/jm2006047
• 作为产物：
  描述：

  5-氨基茚旦 在 三光气 作用下， 以 氯仿 、 丙酮 为溶剂， 反应 10.0h， 生成 5-异硫氰酸茚酯
  参考文献：
  名称：

  疟疾寄生虫二氢乳清酸酯脱氢酶的新型选择性和有效抑制剂：二氢噻吩酮衍生物的发现和优化

  摘要：

  考虑到耐药性的出现和有效抗疟疾疫苗的缺乏，开发用于治疗疟疾的新型抗疟疾剂具有重要意义。在这里，我们阐明了一系列作为恶性疟原虫二氢乳清酸脱氢酶（Pf DHODH）的新型特异性抑制剂的二氢噻吩酮衍生物的发现及其与构效关系。最有前途的化合物50在体外选择性抑制Pf DHODH（IC 50 = 6 nM，相对于h DHODH具有1.4万倍以上的物种选择性）和体外寄生虫生长（IC 50分别针对3D7和Dd2细胞分别为15和18 nM）。此外，由体内药代动力学研究确定化合物50的口服生物利用度为40％。这些结果进一步表明，Pf DHODH是抗疟疾化学疗法的有效靶标，这项工作中报道的新型支架可能会导致发现新的抗疟疾药物。

  DOI：

  10.1021/jm400938g

文献信息

• Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of
  申请人：American Home Products Corporation

  公开号：US05554607A1

  公开（公告）日：1996-09-10

  A method for increasing the HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration, which comprises administering to said mammal, orally or parenterally, a compound of formula I: ##STR1## wherein R is alkyl; a substituted or unsubstituted aromatic N, O or S heterocycle; substituted or unsubstituted aryl, arylalkyl, benzhydryl or indanyl, in which the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkyl or hydroxy; and R.sup.1 is aryl, alkyl, alkenyl, alkynyl or substituted aryl where the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkoxy or hydroxy.

  一种用于增加需要增加高密度脂蛋白胆固醇血浓度的哺乳动物血液中HDL胆固醇浓度的方法，包括向所述哺乳动物口服或静脉注射化合物I的步骤：##STR1##其中R为烷基；取代或未取代的芳香族N、O或S杂环；取代或未取代的芳基、芳基烷基、苯基甲基或茚基，在其中取代基是从烷基、烷氧基、烷硫基、烯基、炔基、卤素、全氟烷基、全氟烷基或羟基组成的群中独立选择的一到三个成员；以及R.sup.1为芳基、烷基、烯基、炔基或取代芳基，其中取代基是从烷基、烷氧基、烷硫基、烯基、炔基、卤素、全氟烷基、全氟烷氧基或羟基组成的群中独立选择的一到三个成员。
• 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives
  申请人：American Home Products Corporation

  公开号：US20020061883A1

  公开（公告）日：2002-05-23

  1 wherein R is alkyl, alkenyl, or alkynyl; R 1 and R 2 are each independently hydrogen alkyl, or aryl; and Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aroyloxy.

  其中R为烷基、烯基或炔基；R1和R2各自独立地为氢、烷基或芳基；Ar为苯基、茚基、苄基或苯基，其上取代一个或多个来自卤素、烷基、全氟烷基、低烷氧基、全氟烷氧基、二烷基胺基和芳酰氧基的基团。
• Amino thioxomethyl amino oxyacetic acid derivatives
  申请人：American Home Products Corporation

  公开号：US20020045776A1

  公开（公告）日：2002-04-18

  Antiatherosclerotic compounds are provided which have the following structure: 1 wherein R is lower alkyl; R 1 is hydroxy, amino, or lower alkoxy, R 2 and R 3 are each independently hydrogen, alkyl or aryl; Ar is phenyl, indanyl, benzhydryl, or phenyl substituted with one or more member selected from the group consisting of halogen, lower alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aryloxy; or pharmaceutically acceptable salts thereof.

  提供了具有以下结构的抗动脉粥样硬化化合物：其中R是较低的烷基；R1是羟基、氨基或较低的烷氧基；R2和R3各自独立地是氢、烷基或芳基；Ar是苯基、茚基、苯甲基或苯基，其中一个或多个成员被选自卤素、较低的烷基、全氟烷基、较低的烷氧基、全氟烷氧基、二烷基氨基和芳氧基组成的群体所取代；或其药用盐。
• [EN] COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS QUI POTENTIALISENT LE RÉCEPTEUR AMPA ET LEURS UTILISATIONS EN MÉDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009053448A1

  公开（公告）日：2009-04-30

  The invention provides compounds of formula (I) and salts thereof wherein R1, R2, R3, R4 and X are as defined in the description. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

  该发明提供了式（I）的化合物及其盐，其中R1、R2、R3、R4和X如描述中所定义。还公开了制备方法、药物组合物以及将其用作药物的用途，例如在治疗由谷氨酸受体功能减少或失衡介导的疾病或症状，如精神分裂症或认知障碍。
• [EN] Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)<br/>[FR] UREE-OCTAHYDROINDOLES SUBSTITUES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR 1 DE L'HORMONE CONCENTRANT LA MELANINE (MCH1R)
  申请人：BIOVITRUM AB

  公开号：WO2005051381A1

  公开（公告）日：2005-06-09

  The invention relates to compounds of the general formula (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, Ar, and X are as defined in the description, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).

  该发明涉及通式（I）的化合物，其中R0、R1、R2、R3、R4、R5、R6、R7、R8、R9、Ar和X如描述中所定义，或其药学上可接受的盐、水合物、几何异构体、消旋体、互变异构体、光学异构体、N-氧化物及其前药形式。这些化合物可用于治疗或预防与MCH1R受体相关的疾病，并用于调节食欲。该发明还涉及该用途以及包含通式（I）化合物的药物配方。